Table 2.

Description of the study sample by stage of NET and whether octreotide treatment was received

Distant stage NET (N = 1,176)Local and regional stage NET (N = 5,764)
Without octreotide treatmentWith octreotide treatmentWithout octreotide treatmentWith octreotide treatment
N (%)N (%)PN (%)N (%)P
Carcinoid syndrome<0.0001<0.0001
 No718 (76.14%)57 (24.46%)5,000 (88.21%)25 (26.04%)
 Yes225 (23.86%)176 (75.54%)668 (11.79%)71 (73.96%)
Age, y0.01540.6322
 65–69223 (23.65%)60 (25.75%)1,600 (28.23%)29 (30.21%)
 70–74242 (25.66%)73 (31.33%)1,426 (25.16%)27 (28.13%)
 75–79217 (23.01%)59 (25.32%)1,259 (22.21%)22 (22.92%)
 ≥80261 (27.68%)41 (17.60%)1,383 (24.40%)18 (18.75%)
Gender0.00790.9175
 Male390 (41.36%)119 (51.07%)2,397 (42.29%)40 (41.67%)
 Female553 (58.64%)114 (48.93%)3,271 (57.71%)56 (58.33%)
Race/ethnicity0.50240.5583
 Non-Hispanic white788 (83.56%)202 (86.70%)4,443 (78.39%)76 (79.17%)
 Non-Hispanic black90 (9.54%)18 (7.73%)647 (11.41%)Maskeda
 Hispanic or others65 (6.89%)13 (5.58%)578 (10.20%)Maskeda
Region0.02050.0416
 Northeast158 (16.76%)55 (23.61%)1,063 (18.75%)29 (30.21%)
 Midwest150 (15.91%)46 (19.74%)910 (16.06%)12 (12.50%)
 South226 (23.97%)46 (19.74%)1,391 (24.54%)20 (20.83%)
 West409 (43.37%)86 (36.91%)2,304 (40.65%)35 (36.46%)
Urban/rural status0.12980.3990
 Metropolitan833 (88.34%)214 (91.85%)5,082 (89.66%)Maskeda
 Nonmetropolitan110 (11.66%)19 (8.15%)586 (10.34%)Maskeda
Census tract median income in quartile0.01010.1984
 First quartile253 (26.83%)42 (18.03%)1,420 (25.05%)21 (21.88%)
 Second quartile221 (23.44%)72 (30.90%)1,419 (25.04%)22 (22.92%)
 Third quartile240 (25.45%)54 (23.18%)1,421 (25.07%)20 (20.83%)
 Fourth quartile229 (24.28%)65 (27.90%)1,408 (24.84%)33 (34.38%)
Census tract % below poverty level in quartile0.04820.5578
 First quartile223 (23.65%)71 (30.47%)1,422 (25.09%)22 (22.92%)
 Second quartile237 (25.13%)57 (24.46%)1,408 (24.84%)30 (31.25%)
 Third quartile234 (24.81%)61 (26.18%)1,421 (25.07%)22 (22.92%)
 Fourth quartile249 (26.41%)44 (18.88%)1,417 (25.00%)22 (22.92%)
Census tract % college in quartile0.06680.1598
 First quartile249 (26.41%)45 (19.31%)1,411 (24.89%)30 (31.25%)
 Second quartile230 (24.39%)64 (27.47%)1,423 (25.11%)18 (18.75%)
 Third quartile225 (23.86%)69 (29.61%)1,422 (25.09%)19 (19.79%)
 Fourth quartile239 (25.34%)55 (23.61%)1,412 (24.91%)29 (30.21%)
Comorbidity score0.52630.6872
 0606 (64.26%)161 (69.10%)3,413 (60.22%)60 (62.50%)
 1155 (16.44%)35 (15.02%)990 (17.47%)16 (16.67%)
 ≥2110 (11.66%)21 (9.01%)788 (13.90%)Maskeda
 Unknown72 (7.64%)16 (6.87%)477 (8.42%)Maskeda
Tumor size0.95760.0005
 <1 cm28 (2.97%)Maskeda1,220 (21.52%)Maskeda
 1–2 cm120 (12.73%)Maskeda1,390 (24.52%)Maskeda
 >2 cm426 (45.17%)102 (43.78%)1,445 (25.49%)38 (39.58%)
 Unknown369 (39.13%)95 (40.77%)1,613 (28.46%)27 (28.13%)
Histology grade<0.00010.3429
 Grade 1705 (74.76%)207 (88.84%)4,960 (87.51%)Maskeda
 Grade 2160 (16.97%)Maskeda470 (8.29%)Maskeda
 Unspecified (either grade 1 or 2)78 (8.27%)Maskeda238 (4.20%)Maskeda
Primary site<0.0001<0.0001
 Larynx, bronchus, lung, trachea, and other respiratory organs262 (27.78%)16 (6.87%)1,508 (26.61%)14 (14.58%)
 Cecum and appendix81 (8.59%)18 (7.73%)347 (6.12%)Maskeda
 Colon81 (8.59%)20 (8.58%)1,123 (19.81%)Maskeda
 Small intestine309 (32.77%)109 (46.78%)1,788 (31.55%)42 (43.75%)
 Pancreas119 (12.62%)40 (17.17%)192 (3.39%)Maskeda
 Others91 (9.65%)30 (12.88%)710 (12.53%)20 (20.83%)
Resection of primary tumor0.34200.0011
 No464 (49.20%)123 (52.79%)900 (15.88%)28 (29.17%)
 Yes479 (50.80%)110 (47.21%)4,768 (84.12%)68 (70.83%)
Resection of liver metastases<0.00010.0021
 No908 (96.29%)201 (86.27%)5,655 (99.77%)Maskeda
 Yes35 (3.71%)32 (13.73%)13 (0.23%)Maskeda
Chemotherapy<0.0001<0.0001
 No806 (85.47%)130 (55.79%)5,351 (94.41%)55 (57.29%)
 Yes137 (14.53%)103 (44.21%)317 (5.59%)41 (42.71%)
Radiotherapy0.22940.4405
 No851 (90.24%)204 (87.55%)5,426 (95.73%)Maskeda
 Yes92 (9.76%)29 (12.45%)242 (4.27%)Maskeda
Year of diagnosis0.04190.1689
 1999–2003374 (39.66%)75 (32.19%)2,181 (38.48%)30 (31.25%)
 2004–2007569 (60.34%)158 (67.81%)3,487 (61.52%)66 (68.75%)
  • aMasked per SEER-Medicare user agreement for confidentiality.